Pluri Inc.
$ 1.82
0.55%
07 Aug - close price
- Market Cap 19,637,000 USD
- Current Price $ 1.82
- High / Low $ 1.82 / 1.82
- Stock P/E N/A
- Book Value -1.78
- EPS -2.90
- Next Earning Report 2026-09-16
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.51 %
- ROE -10.22 %
- 52 Week High 5.68
- 52 Week Low 1.45
About
Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy, utilizing its proprietary technology platform to develop advanced cell-based therapies for oncology and degenerative conditions. With a robust pipeline of therapeutics aimed at addressing critical unmet medical needs, Pluri actively forms strategic collaborations that bolster its research and development capabilities. Committed to revolutionizing patient care, Pluri is well-positioned to become a significant contributor in the biotechnology landscape, driving growth and delivering impactful healthcare solutions.
Analyst Target Price
$12.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-09-17 | 2025-05-13 | 2025-02-11 | 2024-11-12 | 2024-09-18 | 2024-05-09 | 2024-02-12 | 2023-11-13 | 2023-09-12 | 2023-05-09 | 2023-02-13 |
| Reported EPS | -0.65 | -1 | -0.9365 | -0.5323 | -1.0774 | -1.0593 | -1.0138 | -0.1181 | -0.19 | -0.16 | -0.19 | -1.92 |
| Estimated EPS | -0.74 | -0.73 | None | None | None | None | None | -0.32 | -0.32 | -0.31 | -0.3 | -2.56 |
| Surprise | 0.09 | -0.27 | 0 | 0 | 0 | 0 | 0 | 0.2019 | 0.13 | 0.15 | 0.11 | 0.64 |
| Surprise Percentage | 12.1622% | -36.9863% | None% | None% | None% | None% | None% | 63.0938% | 40.625% | 48.3871% | 36.6667% | 25% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-09-16 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLUR
2026-08-04 06:10:11
This article provides a technical analysis of Pluri Inc (PLUR), highlighting its current price momentum score of 4.86 and its position between resistance at $1.92 and support at $1.32, suggesting suitability for range-bound swing trading. It details various technical indicators like MACD, RSI, and moving averages, most of which indicate a "Sell" or "Neutral" signal for the stock. The analysis concludes with a "Neutral" signal based on moving averages and other technical indicators.
2026-08-01 19:14:04
This article provides a risk assessment for Pluri Inc (PLUR), highlighting its current risk score of 2.15, which ranks 234 out of 384 in the Biotechnology & Medical Research industry. It details the company's beta value of 0.66, indicating underperformance in rising markets and smaller declines in falling markets. The assessment also includes various risk metrics such as volatility, maximum drawdown, and liquidity data over different periods.
2026-08-01 09:09:53
This article provides a revenue breakdown for Pluri Inc. (FWB:4DX), highlighting that the largest contribution to its revenue came from Israel, generating 1.13 million EUR last year and 304.35K EUR the year prior. The information is presented within the financial overview section of TradingView.
2026-08-01 04:10:11
Pluri Inc (PLUR) has a weak financial status and low operating efficiency, ranking 368 out of 384 in the Biotechnology & Medical Research industry with a financial score of 5.27. The company's latest quarterly revenue decreased by 60.89% year-over-year, and its net profit saw a 9.74% year-over-year decrease. Key financial metrics such as cash and cash equivalents, total assets, total liabilities, free cash flow, operating profit, and income after tax have not been disclosed by the company.
2026-07-31 07:39:34
Pluri Inc.'s subsidiary, Cellav Health and Aesthetics Ltd., has secured regulatory registration in the UK for its regenerative aesthetics product, Regenativo+. This registration allows commercial marketing of Regenativo+ in the UK market, estimated at $900 million in 2026, and follows previous regulatory progress in the U.S., expanding Pluri's reach into the European medical aesthetics sector. Cellav is actively pursuing commercial partnerships in the UK and seeking further international regulatory approvals.
2026-07-29 03:04:22
This article provides the quarterly and annual income statements for Pluri Inc (PLUR), allowing users to analyze the company's financial performance and operational efficiency. It presents detailed data on various financial metrics, including total revenue, operating expenses, net income, and earnings per share over several fiscal quarters and years. The page also includes frequently asked questions to help users interpret the financial data and understand key metrics for stock analysis.
